Skip to main content

Table 4 Outcome on kidney angiomyolipoma

From: Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

Studies

Volume (cc)

Sum of longest diameter (mm)

Baseline

n

After treatment

n

Mean diff (95 % CI)

Baseline

n

After treatment

n

Mean diff (95 % CI)

Cabrera Lopez 2011

62.6 ± 18.3

17

23.1 ± 7.0

16

−39.5 (−30.15,–48.85)

     

Dabora 2011

     

212 ± 146

36

145 ± 113

28

−67 (−3.55,–130.5)

Davies 2011

     

135.5 ± 135.6

10

62.8 ± 20.1

7

−69.80 (15.39,–154.99)

Overall Effect

    

−39.5 (−48.85, −30.15)

    

−69.03 (−158.05, 12.65)

    

p = <0.00001

    

p = 0.008

Heterogeneity

    

Not applicable

    

Chi2 = 0.01; I2 = 0 %